

## ABROCITINIB/DUPILUMAB/UPADACITINIB For Atopic Dermatitis

## SPECIAL AUTHORIZATION REQUEST FORM Patients may or may not meet eligibility requirements as established

Please complete all required sections to allow your request to be processed.

or may not meet eligibility requirements as e	stablished
by Alberta government sponsored drug	programs.

PAT	IENT INFORMATION						COVE	RAGE TYPE		
LAS	LAST NAME FIRST NAME				INITIAL		berta Blue Cross			
BIR	TH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER		R		Alberta Human Services				
							□ Other			
ADDRESS		CITY	PI	ROV	ROV POSTAL CODE			ID/CLIENT/COVERAGE NUMBER		
PRE	SCRIBER INFORMATION									
	SCRIBER LAST NAME FIRST	NAME INITI	AL	PRESC	RIBE	R PROFESSIC	NAL AS	SSOCIATION REGI	STRATION	
							REGISTRATION	NUMBER		
					CARNA ADA+C					
CITY, PROVINCE PHONE FAX										
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED							
Please provide the following information for ALL requests										
Rec	uested drug	binqo) 🛛 🗌 Dupili	uma	ab (e.g.	Dupi	kent) 🗌 U	padaci	tinib (e.g. Rinvoq	)	
Dia	Diagnosis				Dos	age and freq	uency		Current weight	
	Moderate to severe atopic dermatitis								(kg)	
Other (please specify)										
	nbination therapy	with photothoropy or	imr	munomo	dulat	ing drugs		Voc		
	Will the requested drug be used in combination with phototherapy or immunomodulating drugs									
For patients new to coverage but currently maintained on the requested drug, provide the treatment start date										
	Please provide the following pre-treatment information for NEW requests for treatment-naïve and treatment-experienced patients   1) Pre-treatment Investigator's Global Assessment (IGA) score and date									
1)										
2)										
3)	3) Previous medications and therapies utilized—check all that apply and indicate dose, duration and response to each, or indicate contraindication, if applicable									
	☐ Topical calcineurin inhibitor									
	Conventional systemic immunomodulatory drug (must be steroid sparing). Specify name:									
	Phototherapy									
Please provide the following information for RENEWAL requests and INITIAL requests for treatment experienced patients										
1)	Current EASI score and	l date						T		
2)	For upadacitinib requests to increase the dose to 30 mg, please indicate if the patient hadImage: Second secon									
Add	ditional information relating to request									
PRESCRIBER'S SIGNATURE DATE (YYYY-MM-DD) Please forward this request to Alberta Blue Cross, Clinical Drug Services										
	10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX <b>780-498-8384</b> in Edmonton • <b>1-877-828-4106</b> toll free all other are							toll free all other areas		
	ONCE YOUR REQUEST HAS SUC	CESSFULLY TRANSMI								
The info	The information on this form is being collected and pursuant to sections 20, 21 and 22 of the Health Information Act, and sections 33 and 34 of the Freedom of Information and Protection of Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or health service. If you have any questions regarding the collection or									
Privacy Act, for the purposes of determining or verifying eligibility to participate in a program or receive a benefit, product or nealth service. If you have any questions regarding the collection or use of this information, please contact an Alberta Blue Cross privacy matters representative toll-free at 1-855-498-7302 or write to Privacy Matters, Alberta Blue Cross, 10009 - 108 Street, Edmonton AB T5J 3C5.										

©\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ©† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 60099 (2023/12)

